SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-21-010467
Filing Date
2021-05-05
Accepted
2021-05-05 06:15:25
Documents
48
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 315437
2 ex31-1.htm EX-31.1 17243
3 ex31-2.htm EX-31.2 17213
4 ex32-1.htm EX-32.1 6283
5 ex32-2.htm EX-32.2 6251
  Complete submission text file 0001493152-21-010467.txt   2439150

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE nxen-20210331.xml EX-101.INS 291534
7 XBRL SCHEMA FILE nxen-20210331.xsd EX-101.SCH 30338
8 XBRL CALCULATION FILE nxen-20210331_cal.xml EX-101.CAL 29713
9 XBRL DEFINITION FILE nxen-20210331_def.xml EX-101.DEF 142181
10 XBRL LABEL FILE nxen-20210331_lab.xml EX-101.LAB 239108
11 XBRL PRESENTATION FILE nxen-20210331_pre.xml EX-101.PRE 194102
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

IRS No.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55320 | Film No.: 21891045
SIC: 2834 Pharmaceutical Preparations